Tri Locum Partners LP Inhibrx, Inc. Transaction History

Tri Locum Partners LP

  • $387 Million
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$16.96 - $27.82 $258,945 - $424,755
15,268 New
15,268 $396,000
Q2 2022

Aug 15, 2022
SELL
$8.52 - $25.26 $3.47 Million - $10.3 Million
-406,733 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$19.89 - $43.18 $3.85 Million - $8.36 Million
193,559 Added 90.8%
406,733 $9.06 Million
Q4 2021

Feb 14, 2022
BUY
$26.75 - $46.02 $5.7 Million - $9.81 Million
213,174 New
213,174 $9.31 Million

Others Institutions Holding INBX

# of Institutions
2
Shares Held
25.3K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Tri Locum Partners LP Portfolio

Follow Tri Locum Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email